MEDI-528, now recognized as enokiizumab , represents a innovative therapeutic targeting the IGF-1R , a crucial protein implicated in multiple epidermal diseases . Early clinical results suggest https://antonitbz809945.blog-gold.com/58207168/enokizumab-a-deep-dive-into-medi-528-and-its-potential